GSK reported that it would freeze the prices of its vaccines for five years for developing countries that graduate from GAVI Alliance. By committing to offer GAVI Alliance prices for vaccines against pneumococcal disease, rotavirus and cervical cancer, GSK will support developing country governments as they transition to financing the full cost of their local vaccination programs.
Since its formation in 2000, the GAVI Alliance has helped to fund the immunization of 440 million children in some of the world’s poorest countries. GSK is a long-standing partner of the Alliance and reserves its lowest prices for GAVI-eligible countries, which can be as low as one-tenth of prices in developed countries.
“By 2020, 22 countries with growing economies will graduate from GAVI support. This process allows GAVI to focus resources on the poorest countries, while enabling governments to take increasing responsibility and ownership for vaccination programs over time,” said Andrew Witty, CEO of GSK.
GSK has committed to provide more than 850 million vaccine doses that will help protect up to 300 million children and young girls in the developing world by 2024.